Cell Therapy Potency Assay Summit

Memo

Defining Potency with Practical Assays to Satisfy Regulators Revolutionize your Approach to Potency Assay Development to Confidently Align with the Clinical Outcome and Regulatory Guidelines The 2nd Cell Therapy Potency Assay will gather 100+ experts working to rationally design better potency assays to smooth the path to regulatory approval and minimize hold times with scientifically rigorous and informative potency measurements. Whether you are submitting your first IND or gearing up towards BLA submission, this critical meeting of minds is your premier opportunity to join the likes of bluebird bio, Arsenal Bio, Takeda, Merck, Sana Biotechnology and more, to gain critical updates on regulatory interactions and unpick how industry peers are approaching potency assay development. Leave this meeting equipped with industry insights to understand what potency assays are showing, develop practical, compatible, reproducible assays; and better characterize your cell therapy products for targeted, untargeted, allogeneic and autologous platforms in oncology and non-oncology indications. URLs:Brochure: https://go.evvnt.com/1541932-2?pid=5569 Tickets: https://go.evvnt.com/1541932-3?pid=5569  Date and Time: On Wed, 31 May 2023 07:30 - Fri, 02 Jun 2023 15:45 Venue details: Hilton Boston Back Bay, 40 Dalton Street, Boston, Massachusetts, 02115, United States Prices:Drug Developers | Conference Only: USD 2999.00,Drug Developers | Conference + Workshop: USD 4896.00,Academic | Conference Only: USD 2599.00,Academic | Conference Only + Workshop: USD 4196.00,Vendor | Conference Only: USD 3799.00,Vendor | Conference Only + Workshop: USD 5996.00 Speakers: Abid Mattoo | Senior Scientist Clinical Stage Analytical Development | Takeda Pharmaceutical Co. Ltd., Alex Santos | Senior Associate Scientist | Be Biopharma, Anka Ehrhardt Director | Cell-Based Sciences | Merck and Co, Anu Vasudevan | Senior Scientist | Arsenal Bio, Ben Espen | Principal Quality Engineer | Avobis Bio, Dongfang Liu | Associate Professor and Director Immunoassay Development Program | Rutgers New Jersey Medical School, Emily Lowe | Senior Director Analytical Sciences | Appia Bio, Eric Smith | Director - R and D | Marker Therapeutics, Inc, Fei Xie | Principal Scientist | Allogene Therapeutics, Ilya Shestopalov | Sr.Director, Analytical Development | bluebird bio, Jasmin Kristianto | senior scientist | Sana Biotechnology, Jie Wei Director | Analytical Sciences | Tr1x therapeutics, Jigesha Dholakia | Senior Manager | Sangamo Therapeutics, Jorge S. Burns | Assistant Professor | University of Ferrara, Maayan Portnoy | Senior Manager Quality Control and Analytical Development | Minovia Therapeutics, Mariska ter Haak | Director Analytical Development | IN8bio, Mike Lehmicke | Vice President Science and Industry Affairs | Alliance of Regenerative Medicine, Mike Sadick | Senior Director Chemistry, Manufacturing and Control, Analytical Development | Precision Biosciences, Nathan Hotaling | Senior Data Scientist | National Institute of Health Science, Rachel Langland | Director, Analytical Development | Wugen Inc., Therese Choquette | Head of Analytical Sciences | Tigen Pharma SA, Volker Huppert | Chief Development Officer | Glycostem Therapeutics, Zhu Pirot | Director - Platform Competitive Generic Therapy and Analytical Development | Bayer